This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crittenden, M. Articles by Vile, R. Search for Related Content PubMed PubMed Citation Articles by Crittenden, M. Articles by Vile, R.

Pharmacologically Regulated Production of Targeted Retrovirus from T Cells for Systemic Antitumor Gene Therapy¹

Department of Immunology [M. C.] and Molecular Medicine Program [M. C., M. G., J. C., T. K., J. T., A. R., H. C., R. M. D., K. H., R. V.], Mayo Clinic, Rochester, Minnesota; ARIAD Gene Therapeutics, Cambridge, Massachusetts [T. C.]; Vectorologie Retrovirale et Therapie Genique, INSERM U412, Lyon Cedex 07, France [F. L. C.]; and Hospital Universitario C/San Martin de Porres, Madrid, Spain [L. A. V.]

We aimed to use cell-based carriers to direct vector production to target sites for systemic therapy. We used T cells engineered to express a chimeric T cell receptor that can specifically recognize target cells expressing the tumor-associated carcinoembryonic antigen (CEA). These T cells were modified to produce a retrovirus under tight pharmacological control using the rapamycin-inducible transcriptional regulatory system. The retroviral vectors produced were transcriptionally targeted to CEA-expressing target cells. We found that vector production and transgene expression from these T cells in vitro was dependent on pharmacological induction and expression of CEA in target cells, respectively. Mice bearing metastatic tumors that received cell carriers delivering the HSVtk gene demonstrated a significant increase in survival, but only in response to pharmacological induction of vector production. Interestingly, the therapeutic effect required the presence of the tumor-specific chimeric receptor on T cells. Further studies demonstrated that systemic delivery of tumor-specific T cells to mice bearing metastatic tumors caused recruitment of nonspecific T cells to the tumor site. We hypothesize that this enhanced targeting to tumor sites is responsible for the efficiency of T cell-mediated retroviral gene transfer and that this principle can be used to enhance systemic therapies using immune-cell carriers.

This article has been cited by other articles:

				S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766. [Abstract] [Full Text] [PDF]

				L. Matuszewski, T. Persigehl, A. Wall, W. Schwindt, B. Tombach, M. Fobker, C. Poremba, W. Ebert, W. Heindel, and C. Bremer Cell Tagging with Clinically Approved Iron Oxides: Feasibility and Effect of Lipofection, Particle Size, and Surface Coating on Labeling Efficiency Radiology, April 1, 2005; 235(1): 155 - 161. [Abstract] [Full Text] [PDF]

				V. M. Rivera, G.-p. Gao, R. L. Grant, M. A. Schnell, P. W. Zoltick, L. W. Rozamus, T. Clackson, and J. M. Wilson Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer Blood, February 15, 2005; 105(4): 1424 - 1430. [Abstract] [Full Text] [PDF]

				D. Jevremovic, R. Gulati, I. Hennig, R. M. Diaz, C. Cole, L. Kleppe, F. L. Cosset, R. D. Simari, and R. G. Vile Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H494 - H500. [Abstract] [Full Text] [PDF]